Quantcast

Why Soliton Stock Is Falling Today


What happened

After the company shared long-term clinical data with investors, the stock of Soliton (NASDAQ: SOLY) , a small-cap medical device maker focused on tattoo removal , dropped about 12% as of 2:55 p.m. EST on Monday.

So what

Soliton shared long-term data today from its 26-week proof-of-concept clinical trial that is testing its technology as a way to remove cellulite from the body.

It had previously shared data from this trial that showed that patients reported an initial improvement on the cellulite severity score (CSS) ranging from 20% to 47%, with the average improvement being 29% after three months.

Management shared six-month data today showing that the CSS average result continued to improve and landed at 31%.

Two thumbs up, one with tattoos on the arm

Image source: Getty Images.

The results sound good on the surface, but it is possible that Wall Street wanted to see an even larger improvement and is selling off the stock in response.

Now what

Soliton appears to have a big market opportunity with tattoo removal alone, and that could expand significantly if the company can add on a cellulite indication. But it is still ramping up its manufacturing capabilities and doesn't expect to start pulling in revenue until 2020, so there's a lot of work ahead.

The technology looks very interesting, but it will remain a highly speculative investment until it starts to generate meaningful revenue. So I'm content to root for this company's success from the safety of the sidelines and focus my attention on other opportunities.

10 stocks we like better than Soliton Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Soliton Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of June 1, 2019

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.





This article appears in: Personal Finance , Stocks
Referenced Symbols: CSS , SOLY



More from Motley Fool

Subscribe







Motley Fool
Contributor:

Motley Fool

Market News, Investing












Research Brokers before you trade

Want to trade FX?